Nano Labs Ltd Class A Ordinary Shares (NA)
Nano Labs Ltd Class A Ordinary Shares (NA) is a biotechnology company focused on the development and commercialization of innovative diagnostic and healthcare solutions. The company leverages nanotechnology to enhance the sensitivity and accuracy of diagnostic tests, aiming to improve early detection and management of various health conditions. Nano Labs aims to deliver advanced medical technologies that contribute to better patient outcomes and healthcare efficiency.
Company News
Exosens has signed a contract with the Spanish Ministry of Defense to supply 17,000 night vision monoculars using 16mm 4G intensifier tubes, to be delivered between 2025 and 2028, strengthening its position as a strategic night vision equipment supplier to NATO member states.
The cryptocurrency market reached $4.11 trillion in August 2025, with institutional confidence at unprecedented levels following regulatory breakthroughs and Bitcoin's climb to $122,379. Corporate adoption is transforming digital assets from speculative trades to strategic financial instruments.
Nano Labs reported a significant strategic pivot towards cryptocurrency reserves in H1 2025, reducing operating expenses by 53.5% and accumulating over 128,000 BNB tokens while experiencing a decline in net revenue.